The American group BRISTOL MYERS SQUIBB has paid $7.8 bn in cash for DUPONT PHARMACEUTICALS ($1.5 bn turnover in 2000), DUPONT's "pharmacy" business. The latter thus secured a much higher price that initially expected as analysts were counting on $4 to 7 bn maximum.